Inflammatory Biomarkers as Predictors of PONV Following Pediatric Orchiopexy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-8
SponsorDiskapi Yildirim Beyazit Education and Research Hospital
About this trial
Orchiopexy is a common surgical procedure for the treatment of cryptorchidism in the pediatric population, with a high incidence of postoperative nausea and vomiting (PONV).
Recent evidence suggests that systemic inflammation may contribute to PONV pathogenesis, and preoperative inflammatory biomarkers such as NLR, PLR, SII, MLR, and SIRI could serve as predictive indicators.
This prospective observational study aims to evaluate the relationship between these biomarkers and PONV incidence in children undergoing orchiopexy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged between 1 and 8 years
Patients with ASA physical status I-II
Patients scheduled for elective orchiopexy
Obtained written informed consent from parents/guardians
Disqualifiers
Patients younger than 1 year or older than 8 years
Patients with ASA physical status III or higher
Presence of acute infection signs
History of previous nausea or vomiting
Trial population
Children aged 1-8 years with ASA physical status I-II who are scheduled to undergo elective orchiopexy under general anaesthesia
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Measurement of Preoperative Inflammatory Biomarkers
Other interventionBlood samples will be collected preoperatively to measure inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index, monocyte-to-lymphocyte ratio (MLR), and systemic inflammation response index. These values will be analysed in relation to the incidence of postoperative nausea and vomiting within the first 6 hours after pediatric orchiopexy. No experimental drug or device will be administered as part of the study; all procedures will be conducted within the scope of standard perioperative care.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Incidence of Postoperative Nausea and Vomiting (PONV)
PONV will be assessed using a standardized nausea-vomiting scoring system by an anesthesiologist blinded to biomarker results.
Time frame
Within 6 hours postoperativelySecondary outcomes
1
Need for Antiemetic Treatment
The number of patients who receive at least one dose of rescue antiemetic medication will be recorded within the first 6 hours after surgery.
Time frame
Within 6 hours postoperativelySponsors and contacts
Click on the lead sponsor to view all of their trials.
Diskapi Yildirim Beyazit Education and Research Hospital
Lead sponsor
Ankara Etlik City Hospital
Sponsor institution
Source ClinicalTrials.gov